UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries
Goldman Sachs on Wednesday upgraded shares of Teva Pharmaceutical Industries (NYSE: TEVA) from Sell to Neutral and raised the price target from $40 to $52.
Analyst Jami Rubin expects the “narrative around TEVA to change from concerns around a declining Copaxone franchise to growth and optionality in the underlying business.”
Rubin went on to propose changes management could make such as:
- Cut costs
- Narrow R&D focus
- Divest parts of business
The analyst said mergers & acquisitions are “one of the key drivers of sector performance” and believes Teva could “put about $10bn towards deal activity.”
Shares of Teva are up 1.3 percent to $50.57 in Wednesday's trading and up 26 percent year-to-date.
Latest Ratings for TEVA
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Feb 2022 | Barclays | Maintains | Equal-Weight | |
| Jan 2022 | Argus Research | Downgrades | Buy | Hold |
| Oct 2021 | Raymond James | Downgrades | Outperform | Market Perform |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Goldman Sachs Jami RubinAnalyst Color Analyst Ratings
